Science Raises $400 Million To Expand PRIMA Brain-Computer Interface

Science has raised $400 million in Series D financing, bringing its total capital raised since 2021 to more than $900 million. The funding will support the commercialization of its PRIMA brain-computer interface technology, expansion into additional markets, and continued development of neural interfaces designed to address serious neurological and sensory conditions.

Investors participating in the financing include Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech.

The substantial financing positions Science to expand the availability of PRIMA across Europe while preparing for its anticipated introduction into the United States.

The company will also use the capital to expand its research, manufacturing, and operational capabilities as it advances multiple brain-computer interface technologies.

Science is focused on developing systems that establish connections between the nervous system and external technologies, with the goal of restoring capabilities that have been affected by disease or injury.

Its PRIMA platform represents an important part of that strategy, targeting vision loss associated with certain forms of advanced macular degeneration.

Expanding PRIMA In Europe And The United States

PRIMA is a brain-computer interface designed to restore a degree of functional vision in patients who have lost sight because of certain types of late-stage macular degeneration.

The technology has received CE marking in Europe, allowing it to be made available within the scope of its authorized medical indication.

The regulatory milestone represents an important step toward making the technology accessible to patients who have experienced severe vision loss.

Unlike conventional treatments that primarily aim to slow the progression of retinal disease, PRIMA is designed to help restore a specific form of visual function.

The system focuses on enabling form vision, which includes the ability to recognize shapes and visual information such as letters, numbers, and words.

For individuals with profound vision impairment, recovering even limited form vision could potentially improve their ability to perform certain reading and recognition tasks.

However, the degree of visual function restored may vary between patients, and the technology is not intended to provide the full range of capabilities associated with natural eyesight.

CE marking also does not establish that every patient who meets the treatment criteria will experience the same degree of benefit.

Science plans to use part of its new financing to expand access to PRIMA across European markets, supporting the infrastructure and operational capabilities needed for broader deployment.

Commercial expansion will require coordination among healthcare providers, medical specialists, and other participants involved in evaluating patients and delivering the technology.

As availability increases, the company will also need to support clinical implementation, patient selection, and ongoing evaluation of treatment outcomes.

Preparing For U.S. Regulatory Approval

In parallel with its European expansion, Science is pursuing authorization for PRIMA in the United States.

The company is seeking approval from the U.S. Food and Drug Administration through the Humanitarian Device Exemption pathway.

This regulatory framework is intended for certain medical devices designed to address diseases or conditions affecting relatively small patient populations.

Under this pathway, eligible devices are evaluated according to requirements that differ from those applicable to conventional medical device approvals.

The Humanitarian Device Exemption process considers whether the device meets applicable safety requirements and whether its probable benefit outweighs the risks associated with its use, among other criteria.

For Science, obtaining U.S. authorization would establish an important foundation for introducing PRIMA to eligible American patients.

The company will need to complete the necessary regulatory process before commercializing the device in the United States under the proposed indication.

Approval is not guaranteed, and the timing of a potential U.S. launch will depend on regulatory review and other commercialization requirements.

The $400 million financing provides Science with additional resources to support these efforts while continuing to build its international operations.

Developing Brain-Computer Interfaces For Medical Applications

Science operates within the emerging brain-computer interface industry, which is developing technologies capable of connecting biological neural activity with electronic or engineered systems.

Brain-computer interfaces are being investigated for a variety of medical applications, including restoring communication, movement, and sensory capabilities affected by neurological damage or disease.

These technologies generally seek to create a functional link between the nervous system and an external device or processing system.

The potential applications extend beyond conventional assistive technologies because neural interfaces may directly interact with pathways involved in processing or transmitting information.

Science’s PRIMA platform demonstrates one approach to using neural interface technology to address severe vision loss.

Its development also reflects the growing interest in specialized medical applications where restoring a particular function could provide meaningful benefits to patients.

Commercializing such technologies involves additional challenges beyond demonstrating that a device can operate effectively.

Companies must also establish appropriate clinical procedures, manufacturing consistency, regulatory compliance, and long-term support systems.

These requirements become increasingly important as technologies move from clinical development toward broader patient availability.

Advancing Biohybrid Neural Interface Technology

Beyond PRIMA, Science plans to direct additional financing toward its biohybrid research program.

The initiative is developing a neural interface that integrates engineered neurons with the brain’s existing circuits.

This approach differs from conventional brain-computer interfaces that rely primarily on electronic components to detect or deliver signals associated with neural activity.

A biohybrid system seeks to incorporate living biological elements into the interface between the brain and an engineered technology.

The underlying objective is to explore whether engineered neurons can provide another method of establishing connections with existing neural circuits.

Such technologies may offer new directions for neural interface research, although their effectiveness, safety, and eventual clinical applications will need to be established through further development and validation.

Integrating engineered biological systems with the human nervous system presents complex scientific and technical challenges.

Researchers must consider how introduced cells interact with existing neural tissue, how reliably information can be transmitted, and whether the resulting interface can maintain stable functionality.

Long-term biological compatibility and safety will also be important considerations as these technologies advance.

Science’s investment in the biohybrid program reflects an effort to pursue multiple approaches to neural interfacing rather than relying exclusively on a single device architecture.

While PRIMA represents a technology moving toward broader commercial deployment, the biohybrid program is part of the company’s longer-term research and development strategy.

Expanding Manufacturing And Operational Infrastructure

A portion of the Series D financing will support Science’s manufacturing capacity and operational infrastructure.

Building the infrastructure required to produce and distribute advanced medical devices is a critical component of commercial expansion.

Neural interface systems must meet demanding standards for quality, consistency, and reliability, particularly when used in medical procedures involving sensitive biological structures.

As Science expands the availability of PRIMA, it will need sufficient manufacturing and operational capabilities to support deployment across multiple healthcare markets.

The company also plans to strengthen its research infrastructure, supporting ongoing improvements to existing technologies and the development of future neural interface systems.

These investments may help Science manage the transition from a research-focused organization toward a company with larger commercial operations.

The financing also gives the company additional flexibility to pursue regulatory milestones, support clinical activities, and develop its broader technology portfolio.

Building A Larger Neural Technology Platform

With more than $900 million raised since 2021, Science has secured substantial capital to pursue its vision of developing medical technologies that interact directly with the nervous system.

The latest $400 million Series D round underscores investor interest in neural interfaces and their potential medical applications.

Science’s immediate priorities center on expanding PRIMA in Europe and pursuing U.S. regulatory authorization.

At the same time, the company is investing in next-generation technologies through its biohybrid research program.

The combination of commercial expansion and longer-term research positions Science to pursue opportunities across different stages of neural interface development.

Its progress will depend on translating technological advances into reproducible clinical outcomes, obtaining necessary regulatory authorizations, and building the infrastructure required for reliable commercial deployment.

For PRIMA, the near-term opportunity is to broaden access to a technology designed to restore form vision for certain patients with advanced macular degeneration.

For the broader company, the Series D financing provides resources to advance additional approaches to connecting engineered systems with the human nervous system.

The investment marks another step in Science’s effort to establish a larger medical technology platform around brain-computer interfaces, with potential applications extending beyond its initial focus on vision restoration.